Hiroshi Yabusaki

6.8k citations

142 papers · 3.6k indexed · 3 hit papers · h-index 22

Gastroenterology top 0.5%
- Gastrointestinal Tumor Research and Treatment 60
Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes 113
- Metastasis and carcinoma case studies 60
Oncology top 2%
- Colorectal Cancer Treatments and Studies 22
- HER2/EGFR in Cancer Research 11
Surgery top 1%
- Cholangiocarcinoma and Gallbladder Cancer Studies 22
- Esophageal Cancer Research and Treatment 12
- Esophageal and GI Pathology 11
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Atsushi Nashimoto Norio Aoyama Soji Ozawa Hiroyasu Igaki Masayuki Shinoda Haruhiko Fukuda Akira Kurita Tsutomu Nakamura
Cited by: Gastroenterology Pulmonary and Respiratory Medicine Oncology
Partner nations: Japan United States South Korea

In The Last Decade

Hiroshi Yabusaki

133 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
2018 Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial
2011 A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

Peers

Countries citing papers authored by Hiroshi Yabusaki

Since Specialization

Citations

This map shows the geographic impact of Hiroshi Yabusaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Yabusaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Yabusaki more than expected).

Fields of papers citing papers by Hiroshi Yabusaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Yabusaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Yabusaki. The network helps show where Hiroshi Yabusaki may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hiroshi Yabusaki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hiroshi Yabusaki Line = papers co-authored together Hiroshi Yabusaki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study Shigenori Kadowaki,Tomoyuki Otsuka,Keiko Minashi,Shinichi Nishina,Hiroshi Yabusaki,Chiaki Inagaki,Tomohiro Nishina,Hisateru Yasui,Hiroshi Matsuoka,Nozomu Machida,Masahiro Tsuda,Fumio Nagashima,Hisashi Hosaka,Junichi Matsubara,Hiroyuki Arai,Satoshi Ida,Yuya Kimijima,Yuko Matsuda,Manabu Muto,Kei Muro	2025	0
2	LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer Kohei Shitara,Sun Young Rha,Lucjan Wyrwicz,Takashi Oshima,Nina Karaseva,M. A. Osipov,Haruna Yasui,Hiroshi Yabusaki,S. G. Afanasyev,Park Yk,S-E. Al-Batran,Takaki Yoshikawa,P.E. Yanez Weber,Maria Di Bartolomeo,Sara Lonardi,X. Fang,C-S. Shih,P. Bhagia,Y-J. Bang	2024	7
3	Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy Hiroshi Ichikawa,Masaki Aizawa,Yosuke Kano,Takaaki Hanyu,Yusuke Muneoka,Sou Hiroi,Hiroto Ueki,Kazuki Moro,Yuki Hirose,Kohei Miura,Yoshifumi Shimada,Jun Sakata,Hiroshi Yabusaki,Satoru Nakagawa,Takashi Kawasaki,Shujiro Okuda,Toshifumi Wakai	2024	6
4	Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study Toshifumi Yamaguchi,Atsuo Takashima,Kengo Nagashima,Koshi Kumagai,Tatsuya Yamada,Masanori Terashima,Hiroshi Yabusaki,Kazuhiro Nishikawa,Kazuaki Tanabe,Gen Yunome,Yasuyuki Kawachi,Takanobu Yamada,Takeo Fukagawa,Takahiro Kinoshita,Masaya Watanabe,Koshiro Ishiyama,Kentaro Inoue,Narikazu Boku	2023	5
5	Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial Kensei Yamaguchi,Yung‐Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min‐Hee Ryu,Daisuke Sakai,Hyun Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Tatsu Shimoyama,Keun‐Wook Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kohei Shitara	2022	76
6	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7) Hisato Kawakami,Shuichi Hironaka,Taito Esaki,Kazuaki Chayama,Masahiro Tsuda,Naotoshi Sugimoto,Shigenori Kadowaki,Akitaka Makiyama,Nozomu Machida,Hidekazu Hirano,Kenro Hirata,Hiroki Hara,Hiroshi Yabusaki,Yoshito Komatsu,Kei Muro	2021	14
7	Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial Masanori Tokunaga,Yukinori Kurokawa,Ryunosuke Machida,Yuya Sato,Shuji Takiguchi,Yuichiro� Doki,Hiroshi Yabusaki,Masaya Watanabe,Shinji Hato,Mikihito Nakamori,Seiji Ito,Takaki Yoshikawa,Masanori Terashima	2020	56
8	Incidence of Multiple Metachronous Gastric Cancers After Pyloric‐Preserving Gastrectomy Masaki Aizawa,Hiroshi Yabusaki,Atsushi Matsuki,Takeo Bamba,Satoru Nakagawa	2020	4
9	128P Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090 Chigusa Morizane,Makoto Ueno,T. Ioka,Masahiro Tajika,Masafumi Ikeda,Kensei Yamaguchi,Hiroki Hara,Hiroshi Yabusaki,Atsushi Miyamoto,Satoru Iwasa,Manabu Muto,Tsutomu Takashima,Keiko Minashi,Yoshito Komatsu,Tomohiro Nishina,Takako Eguchi Nakajima,Takatoshi Sahara,Setsuo Funasaka,Masakazu Yashiro,Junji Furuse	2020	2
10	A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1) Takaki Yoshikawa,Masanori Terashima,Junki Mizusawa,Souya Nunobe,Yasunori Nishida,M Kaji,Noriyoshi Fukushima,Shinji Hato,Yasuhiro Choda,Hiroshi Yabusaki,Kazuhiro Yoshida,Seiji Ito,Atsushi Takeno,Takashi Yasuda,Yasuyuki Kawachi,Hokahiro Katayama,Haruhiko Fukuda,Narikazu Boku,Takeshi Sano,Mitsuru Sasako	2017	5
11	Risk Factors of DVT in the Patients After Colorectal Surgery Atsuko Usuda,Yasumasa Takii,Atsushi Matsuki,Satoru Nakagawa,Hiroshi Yabusaki,Atsushi Nashimoto,Yuji Okura	2012	1
12	A Case of Advanced Gastric Cancer with Abdominal Paraaortic and Virchow's Lymph Node Metastasis Responding to Pathological CR After Preoperative Combined Docetaxel, Cisplatin, and S^\|^ndash;1 Chemotherapy Isaya Hashimoto,Atsushi Nashimoto,Hiroshi Yabusaki,Satoru Nakagawa,Atsushi Matsuki	2011	0
13	Long-Term Clinical Outcome and Survival after Pylorus-Preserving Gastrectomy Atsushi Matsuki,Atsushi Nashimoto,Hiroshi Yabusaki,Satoru Nakagawa	2011	10
14	A Case of Duodenal Cancer with Familial Adenomatous Polyposis Treated by Pancreas-sparing Duodenectomy Masayuki Nagahashi,Yoshiaki Tsuchiya,Tatsuya Nomura,Atsushi Nashimoto,Hiroshi Yabusaki,Yasumasa Takii,Satoru Nakagawa,Otsuo Tanaka,Toshiyuki Kato,Tamaki Ohta	2008	1
15	A Case of Coexisting Malignant Lymphoma and Adenocarcinoma Occurring as a Collision Tumor in the Remnant Stomach after Distal Gastrectomy Satoshi Takahashi,Atsushi Nashimoto,Satoru Nakagawa,Hiroshi Yabusaki,Tamaki Ohta	2008	1
16	[Evaluation of neoadjuvant chemotherapy with paclitaxel, 5-fluorouracil and cisplatin for advanced gastric cancer with pyloric stenosis]. Kentaro Yamaguchi,Satoru Nakagawa,Hiroshi Yabusaki,Atsushi Nashimoto	2007	1
17	Critical Evaluation of Jejunal Pouch Interposition after Proximal Gastrectomy for Early Gastric Cancer. Hiroshi Yabusaki,Atsushi Nashimoto,Otsuo Tanaka,Yasumasa Takii,Yoshiaki Tsuchiya,Juei Sasaki	2001	3
18	Clinical Significance of Washing Cytology. Atsushi Nashimoto,Hiroshi Yabusaki,Yoshiaki Tsuchiya,Mitsuhiro TSUTSUI,Otsuo Tanaka,Jyuei SASAKI	1999	2
19	Clinicopathologic Study on Poorly Differentiated Gastric Carcinoma with Medullary Growth Pattern. Kikuo Aizawa,Tetsuya Tada,Satoshi Suzuki,Hiroshi Yabusaki,Norio Tanaka,Shinsuke Tanaka,Kazuo Watanabe,Ichiro Muto,Norio Katayanagi,Tadashi Nishimaki,Tsutomu Suzuki,Otsuo Tanaka,Terukazu Muto,Jun Soga	1992	1
20	Study on esophageal cancer associated with other primary cancers. Norio Katayanagi,Terukazu Muto,Otsuo Tanaka,Tsutomu Suzuki,Kikuo Aizawa,Tadashi Nishimaki,Yoïchi Tanaka,Ichiro Muto,Nobuo Takeda,Shinsuke Tanaka,Shigeru Suzuki,Norio Tanaka,Hiroshi Yabusaki,Katsutoshi Ohmori,Tetsuya Tada,Satoshi Suzuki,Ichio Obinata,Jun Soga	1991	1

About Hiroshi Yabusaki

Hiroshi Yabusaki is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine and Oncology, having authored 142 papers that have together received 3.6k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (113 papers), Gastrointestinal Tumor Research and Treatment (60 papers), Metastasis and carcinoma case studies (60 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (22 papers), Colorectal Cancer Treatments and Studies (22 papers), Esophageal Cancer Research and Treatment (12 papers), HER2/EGFR in Cancer Research (11 papers) and Esophageal and GI Pathology (11 papers). The work is most often cited by research in Gastroenterology (795 citations), Pulmonary and Respiratory Medicine (2.6k citations) and Oncology (1.3k citations). Hiroshi Yabusaki has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Atsushi Nashimoto, Norio Aoyama, Soji Ozawa, Hiroyasu Igaki, Masayuki Shinoda, Haruhiko Fukuda, Akira Kurita, Tsutomu Nakamura, Hideaki Shimizu and Hoichi Kato.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact